Fibroblast Growth Factor Signaling Potentiates VE-Cadherin Stability at Adherens Junctions by Regulating SHP2 by Hatanaka, Kunihiko et al.
Fibroblast Growth Factor Signaling Potentiates VE-
Cadherin Stability at Adherens Junctions by Regulating
SHP2
Kunihiko Hatanaka
1¤, Anthony A. Lanahan
1, Masahiro Murakami
1*
., Michael Simons
1,2.
1Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, United States of America,
2Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut, United States of America
Abstract
Background: The fibroblast growth factor (FGF) system plays a critical role in the maintenance of vascular integrity via
enhancing the stability of VE-cadherin at adherens junctions. However, the precise molecular mechanism is not well
understood. In the present study, we aimed to investigate the detailed mechanism of FGF regulation of VE-cadherin
function that leads to endothelial junction stabilization.
Methods and Findings: In vitro studies demonstrated that the loss of FGF signaling disrupts the VE-cadherin-catenin
complex at adherens junctions by increasing tyrosine phosphorylation levels of VE-cadherin. Among protein tyrosine
phosphatases (PTPs) known to be involved in the maintenance of the VE-cadherin complex, suppression of FGF signaling
reduces SHP2 expression levels and SHP2/VE-cadherin interaction due to accelerated SHP2 protein degradation. Increased
endothelial permeability caused by FGF signaling inhibition was rescued by SHP2 overexpression, indicating the critical role
of SHP2 in the maintenance of endothelial junction integrity.
Conclusions: These results identify FGF-dependent maintenance of SHP2 as an important new mechanism controlling the
extent of VE-cadherin tyrosine phosphorylation, thereby regulating its presence in adherens junctions and endothelial
permeability.
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Introduction
Regulation of endothelial permeability is crucial for many
essential vascular functions including the passage of molecules and
cells through the endothelium without altering structural integrity
of blood vessels [1,2].
The maintenance of the vascular barrier function is largely
achieved by endothelial cell junctions which are comprised of
a complex network of adhesive proteins organized into tight
junctions and adherens junctions [3,4]. The formation of
adherens junctions is required for the correct organization of
tight junctions; therefore, assembly and disassembly of adherens
junction is strictly controlled and critically important for the
overall endothelial homeostasis [5]. Among molecules localized at
adherens junctions, VE-cadherin, a transmembrane homophilic
adhesion receptor, plays a key role in this regulation. Although
VE-cadherin has been regarded as primarily involved in
mediating intercellular adhesion and controlling vascular perme-
ability, recent studies began to reveal its more diverse in-
volvement in a wide variety of vascular functions [6,7]. VE-
cadherin interacts, via its cytoplasmic domain, with three
proteins of the armadillo family: p120-catenin, b-catenin, and
plakoglobin. p120-catenin binds VE-cadherin at the juxtamem-
brane domain of its cytoplasmic tail, preventing internalization
and degradation of VE-cadherin, thereby maintaining cell-cell
adhesion [8]. Permeability-increasing agents such as histamine,
tumor necrosis factor-alpha, platelet-activating factor, and
vascular endothelial growth factor (VEGF) induce phosphoryla-
tion of the VE-cadherin-catenin complex [9,10,11,12,13]. Src-
induced phosphorylation of Y658 or Y731 of VE-cadherin
prevents binding of p120-catenin and b-catenin, respectively,
which increases endothelial permeability and is sufficient to
maintain cells in a mesenchymal state [14,15]. Moreover,
phosphorylation of specific VE-cadherin tyrosines is also induced
by leukocyte adhesion to the endothelium via intercellular
adhesion molecule 1 (ICAM-1), facilitating leukocyte trans-
migration [16,17]. Phosphorylation of VE-cadherin appears to
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protein tyrosine phosphatases (PTPs) including DEP-1, VE-PTP
(PTPb), PTPm, PTP1B and SHP2 are capable of depho-
sphorylating VE-cadherin or associating proteins and are
implicated in functional modification of the VE-cadherin-catenin
complex [18,19,20,21,22].
We have recently found, using in vitro and in vivo approaches,
that inhibition of fibroblast growth factor (FGF) signaling impairs
vascular integrity in the adult vasculature [23]. Specifically, the
lack of endothelial FGF signaling leads to dissociation of p120-
catenin from VE-cadherin and displacement of VE-cadherin
from cell-cell contacts. This, in turn, progresses to the
disorganization of endothelial cell junctions, leading to severe
impairment of endothelial barrier function. In this study, we
investigated molecular mechanisms involved in FGF-dependent
regulation of VE-cadherin phosphorylation and permeability
control. We found that FGF signaling controls VE-cadherin
phosphorylation by regulating SHP2 expression and function
rather than modifying the activity of VE-cadherin kinases. The
absence of FGF signaling leads to impaired SHP2 expression and
reduces its binding to VE-cadherin which, in turn, enhances
tyrosine phosphorylation of VE-cadherin including the Y658 site
required for VE-cadherin-p120-catenin interaction. This defect
was fully reversed by SHP2 overexpression in endothelial cells
with suppressed FGF signaling. We conclude, therefore, that
FGF signaling potentiates VE-cadherin stability at adherens
junctions by regulating SHP2 expression.
Methods
Reagents and Antibodies
Antibodies against the following antigens were commercially
obtained: VE-cadherin, p120-catenin, SHP2, PTPb, DEP-1,
PTP1B, c-Src (Santa Cruz Biotechnology), PTPm, phospho-
tyrosine 416 Src, phospho-tyrosine 527 Src, Fak, phospho tyrosine
397 Fak (Cell Signaling technology), phospho-tyrosine 658 VE-
cadherin, phospho-tyrosine 731 VE-cadherin (invitrogen), HA
(COVANCE), and b-tubulin (Sigma). Anti phospho-tyrosine 685
VE-cadherin antibody was generated in our laboratory.
Cell Culture and Adenoviral Transduction
Bovine aortic endothelial cells (BAEC) and Human umbilical
vein endothelial cells (HUVEC) were purchased from Lonza, and
were cultured at 37uCi n5 %C O 2 in EGM-2 medium (Lonza).
Adenovirus carrying the truncated form of FGF receptor 1 lacking
the cytoplasmic part of the receptor (FGFR1DN) was generated as
previously described [23]. Adenovirus carrying PTPN11 (SHP2)
was obtained from VECTOR BIOLABS. Adenoviral vectors were
transduced at a multiplicity of infection (MOI) of 10–100 vp/cell.
The infection medium was replaced 6 hours later with normal
growth medium. For soluble FGFR (sFGFR) experiments,
adenovirus encoding GFP (control), sFGFR1-IIIc or sFGFR3-IIIb
was transduced in BAEC [23], conditioned media from trans-
duced BAEC were collected two days later, then transferred to
uninfected BAEC. Total cell lysates were extracted 24 hrs after
medium transfer.
GFP-tagged VE-cadherin Construct and Transfection of
Endothelial Cells
cDNA of human VE-cadherin fused in-frame with GFP at the
C-terminus (VE-cadherin-GFP) was a kind gift from Dr. Sunil K.
Shaw (Women and Infants’ Hospital, Providence, RI) [24]. VE-
cadherin-GFP was subcloned into pcDNA3.1 (Invitrogen). A
tyrosine to phenylalanine (Y to F) mutation at VE-cadherin Y658
site (Y658F) was introduced using the QuickChange site-directed
mutagenesis kit (Stratagene). Plasmids were transfected into BAEC
using FuGENE 6 Transfection Reagent (Roche) following the
manufacture’s instruction.
Lentivirus Vector Construct and Transduction of
Endothelial Cells
Human SHP2 constructs (wild-type and C/S mutant) were
purchased from Addgene and subcloned into pLVX-IRES-puro
lentiviral expression vector (Clontech). Lentivirus packaging and
envelope vectors, pMDLg/pRRE, pRSV-Rev and pMD2.G, were
also purchased from Addgene. These plasmids were cotransfected
into HEK-293T cells to produce a recombinant lentivirus stock
[25].
BAEC on a 6-well plate were cultured in EGM-2 medium
(Lonza) to 50–60% confluent. Lentivirus was added to the cells
with 5 mg/ml polybrene and the 6-well plate was centrifuged at
2300 rpm for 90 min at 37uC following an 8-hour incubation at
37uC with 5% CO2. To obtain stable infected cells, the cells were
selected with 1 mg/ml puromycin.
Immunofluorescence
Immunocytochemistry was performed with a standard pro-
cedure using antibodies described above. Cells were fixed in 2%
paraformaldehyde in phosphate buffered saline (PBS) for 15 min
at room temperature (RT), permeabilized in 0.1% Triton-X in
PBS for 5 min at RT, and blocked in Image-iT FX signal
enhancer (Invitrogen) for 30 min at RT. Coverslips were in-
cubated in primary antibody at 4uC overnight, washed three times
in PBS and then incubated with Alexa Fluor-conjugated secondary
antibodies (Invitrogen) for 1 hour at RT. Then the coverslips were
washed three times in PBS and mounted using Fluoro-Gel
(Electron Microscopy Sciences). Images were captured using Zeiss
510 laser scanning confocal microscopy. Gap formation of the
monolayer was analyzed using immunostaining images in which
the proportion of the gap area between cells to the total image area
was calculated using NIH Image J software.
Permeability Assay
Transendothelial electrical resistance, an index of endothelial
cell barrier function, was measured in real time using an electric
cell-substrate impedance sensing (ECIS) system (ECIS 1600,
Applied BioPhysics) [15,23]. Cells were plated on sterile 8-
chambered gold-plated electrode arrays (8W10E plus) precoated
with fibronectin and grown to full confluence. The electrode
arrays were mounted on the ECIS system within an incubator
(37uC, 5% CO2) and connected to its recorder device. Monolayer
resistance was recorded at 15 kHz in 5-minute intervals.
Western Blotting and Immunoprecipitation
Cells were washed twice with ice-cold PBS and lysed in RIPA
buffer: 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP40,
0.5% sodium deoxycholate, 0.1% SDS, and 16 Complete
protease inhibitor mixture (Roche) and PhosSTOP Phosphatase
inhibitor cocktail (Roche). For evaluation of VE-cadherin phos-
phorylation, lysis buffer was supplemented with freshly prepared
pervanadate (300 mM) [26]. Whole cell lysates were subjected to
SDS-PAGE followed by immunoblotting with the antibodies
described above. For immunoprecipitation assays, whole cell
lysates were harvested with HEPES lysis buffer with NP-40
(50 mM HEPES pH 7.4, 150 mM NaCl, 1% NP-40, 5 mM
EDTA and 16Complete protease inhibitor mixture, (Roche) and
PhosSTOP Phosphatase inhibitor cocktail (Roche) supplemented
FGF Regulation of VE-Cadherin Function via SHP2
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antibody and Dynabeads Protein G (Invitrogen). Isotype-matched
IgG was used as a negative control. Beads were washed 4 times
with PBS, boiled in SDS-PAGE loading buffer, and resolved by
SDS-PAGE [27].
Quantitative Real-time PCR
RNA preparation and cDNA synthesis were described pre-
viously [28]. Total RNA was isolated with an RNeasy Plus Mini
Kit (Qiagen), and cDNA was synthesized using a High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems). PCR
amplification was carried out with gene specific primers: bovine
SHP2, forward 59-TGATTCGCTGTCAGGAACTG; reverse 59-
TGTGCCCAATGTTTCTACCA-39, bovine GAPDH, forward
59-GGCGCCAAGAGGGTCAT-39; reverse 59-
GTGGTTCACGCCCATCACA-39, using Ssofast EvaGreen
Supermix (Bio-Rad) on a CFX96
TM Real-Time PCR Detection
System.
Statistics
Data were expressed as mean 6 SD. Comparison between
groups were performed with a two-tailed Student’s t test. Results
were considered significant at P,0.05.
Results
Disruption of FGF Signaling Affects Endothelial
Monolayer Integrity and Permeability
To investigate the role of FGF signaling in the vasculature, we
employed a dominant negative construct of FGF receptor 1
(FGFR1DN) capable of heterodimerizing with all four isoforms of
FGF receptors, thereby inhibiting overall FGF signaling [29].
First, we tested the effect of suppression of FGF signaling on
endothelial permeability. Ad-FGFR1DN transduction of BAEC
resulted in a dose-dependent decrease in transendothelial re-
sistance compared with control cells (Fig. 1A). Adherens junctions
in the endothelium play a central role in regulation of vascular
permeability. Since VE-cadherin is the principal protein regulating
not only adherens junction formation, but also endothelial
permeability by opening paracellular junctions, we evaluated
VE-cadherin expression and distribution in cells lacking FGF
signaling. While VE-cadherin and p120-catenin localize at cell-cell
contacts in the control BAEC monolayer, (Fig. 1B), BAEC
transduced with Ad-FGFR1DN showed the loss of VE-cadherin
and p120-catenin from cell-cell junctions (Fig. 1C, arrows).
Exposure of BAEC with a higher dose of Ad-FGFR1DN resulted
in the gap formation between endothelial cells (Fig. 1D, arrows).
No gap formation was observed in Ad-GFP transduced cells
(Fig. 1B). Thus, basal FGF signaling is necessary for VE-cadherin
stability at adherens junctions.
FGF Signaling Regulates VE-cadherin-p120-catenin
Association through Modulating VE-cadherin
Phosphorylation Level
Previous reports support the idea that VE-cadherin stability at
adherens junctions is dependent on the phosphorylation status of
VE-cadherin, which modulates VE-cadherin/p120-catenin in-
teraction required for the retention of the VE-cadherin complex at
cell-cell contacts [8,30]. As shown in Fig. 2A, shutdown of FGF
signaling resulted in enhanced tyrosine phosphorylation of VE-
cadherin. In contrast, p120 tyrosine phosphorylation was not
affected by FGF inhibition, suggesting that FGF signaling
primarily controls endothelial permeability through modulating
VE-cadherin phosphorylation (Fig. 2B). In the cytoplasmic tail of
VE-cadherin, at least five tyrosine (Y645, Y658, Y685, Y731 and
Y733) and one serine (S665) residues can be phosphorylated in vitro
and are thought to be involved in the regulation of endothelial
permeability and leukocyte transmigration [14,17,31,32,33]. De-
phosphorylation of Y658 is essential for p120-catenin binding and
VE-cadherin stability at adherens junctions [14,15]. Therefore, we
wished to identify the tyrosine site involved in the FGF-mediated
VE-cadherin stabilization. Western blotting with phospho-specific
antibodies demonstrated that suppression of FGF signaling
increased Y658 phosphorylation while phosphorylation of Y685
and Y731 sites was not affected (Fig. 2C, D). Since it has been
demonstrated that VEGF-A is capable of phosphorylating Y658 in
the cytoplasmic domain of VE-cadherin, thus disrupting the VE-
cadherin complex in adherens junctions [14], we examined the
effect of VEGF-A in endothelial cells defective in FGF signaling.
Although VEGF-A induced Y658 VE-cadherin phosphorylation
in either non-transduced or Ad-GFP transduced endothelial cells
as has been reported previously [34,35], Y658 phosphorylation in
Ad-FGFR1DN transduced cells was increased at baseline and no
further induction was observed after VEGF-A stimulation (Fig. 2E).
While this observation is consistent with our result in Fig. 2A and
2C, cancellation of the VEGF effect in FGFR1DN cells may be
due to VEGFR2 downregulation in endothelial cells lacking FGF
signaling that has been demonstrated in the previous study [36].
To further confirm the FGF effect on VE-cadherin phosphor-
ylation, we employed a soluble FGF receptor (FGF-trap) as an
alternative means to inhibit FGF signaling. sFGFR has been
extensively evaluated and shown to be an effective inhibitor of
FGF signaling both in vitro and in vivo [23]. Using the
conditioned medium containing sFGFR1-IIIc which has the
capacity to bind multiple FGF ligands, we were able to reproduce
the results obtained using Ad-FGFR1DN. In contrast, sFGFR3-
IIIb which binds a very small subset of FGF ligands with low
affinities and does not affect vascular permeability had little effect
on Y658 VE-cadherin phosphorylation (Fig. 2F, G) [37]. In line
with these observations, co-immunoprecipitation experiments
showed that, in cells expressing the dominant negative FGFR1
construct, p120-catenin association with VE-cadherin was im-
paired (Fig. 2H). Furthermore, to confirm that the Y658 site of
VE-cadherin is the real target of FGF signaling, we examined the
effect of FGF inhibition on VE-cadherin mutant carrying tyrosine
to phenylalanine (dephospho-mimetic) mutation of the Y658 site
(Y658F). In HUVEC, while exogenously transfected wild-type
(WT) VE-cadherin localized at cell-cell junctions as expected
(Fig. 2I), junctional localization of WT-VE-cadherin was no longer
detected in cells lacking FGF signaling (Fig. 2J, L). Y658F VE-
cadherin, however, was able to rescue the FGFR1DN effect and
localize at cell-cell junctions even in the absence of FGF signaling
(Fig. 2K, L). Thus, we concluded that VE-cadherin phosphory-
lation is a downstream event of FGF signaling, and inhibition of
FGF signaling increases Y658 phosphorylation, thereby disrupts
VE-cadherin-based junction stability.
FGF Signaling is Required for SHP2 Expression and SHP2-
VE-cadherin Association
Next we investigated the molecular mechanism of FGF-
dependent regulation of VE-cadherin phosphorylation. Src has
been identified as a kinase responsible for VE-cadherin Y658
phosphorylation [14]. To examine the possibility that FGF
signaling modulates Y658 phosphorylation by regulating Src
activity, we evaluated phosphorylation status of Src Y416 that is
considered to be an indicator of Src activity. As shown in Fig. 3A,
B, phosphorylation levels of Src Y416 site was not increased in
FGF Regulation of VE-Cadherin Function via SHP2
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Y527 phosphorylation which inhibits Src activation did not
change in these cells either, further suggesting that FGF inhibition
does not result in Src activation that could lead to VE-cadherin
phosphorylation (Fig. 3A, C). Focal adhesion kinase (FAK) is also
reported to regulate VE-cadherin phosphorylation levels [38];
however, phosphorylation levels of FAK were not increased in
cells lacking FGF signaling (Fig. 3A, D).
Since activity of two known kinase controlling VE-cadherin
phosphorylation was not affected, we then evaluated the possibility
that a PTP, but not a kinase, is responsible for modulating Y658
VE-cadherin phosphorylation. Among PTPs, DEP-1 (CD148),
VE-PTP (PTPb), PTPm, PTP1B and SHP2 have been implicated
in the interaction with the VE-cadherin-catenin complex and/or
regulation of VE-cadherin function by modifying its phosphory-
lation status [18,20,21,22,39]. We found that suppression of FGF
signaling impaired SHP2 expression while the expression levels of
other PTPs were not affected (Fig. 3E, F. G). Under baseline
conditions, SHP2 co-immunoprecipitated with VE-cadherin;
however, expression of the FGFR1DN construct fully abolished
this interaction (Fig. 3H, I).
These results suggest the possibility that SHP2 bound to VE-
cadherin may regulate the phosphorylation level of VE-cadherin
Y658 site. To formally evaluate this, we tested the effect of
inhibition of SHP2 activity on VE-cadherin Y658 phosphoryla-
tion. Expression of the C/S mutant of SHP2 (a catalytically
inactive form) in BAEC led to an increase in VE-cadherin Y658
phosphorylation compared to SHP2 overexpressing cells or
control cells (Fig. 3J), while overexpression of SHP2 does not
affect VE-cadherin expression levels (not shown).
SHP2 Expression is Controlled Post Translationally by FGF
Signaling
To determine the mechanism of SHP2 down-regulation by FGF
signaling shutdown, we next tested whether FGF signaling controls
SHP2 expression at the transcriptional or post translational level.
Quantitative analyses of SHP2 mRNA levels using real-time
quantitative PCR in BAEC transduced with Ad-FGFR1DN
showed an increase in mRNA abundance while the control virus
had no effect (Fig. 4A). This excludes the possibility that FGF
inhibition decreases SHP2 expression through a transcriptional
Figure 1. FGF signaling is necessary for endothelial cell monolayer integrity. A. Endothelial monolayer permeability evaluated with the
ECIS system. Transendothelial resistance was measured every 5 minutes for 20 hours after the onset of adenoviral transduction. The experiment
reported has been performed 3 times with comparable results. Note that cells lacking FGF signaling showed decreased transendothelial resistance
(increased endothelial permeability). B, C, D. VE-cadherin was absent from cell-cell contacts in cells lacking FGF signaling. Immunostaining of
quiescent and fully confluent BAEC transduced with Ad-GFP (B) or Ad-FGFR1DN (C: MOI=10, D: MOI=100). Cells were stained for VE-cadherin (red)
and p120-catenin (green). Note that VE-cadherin was absent from cell-cell contacts (arrows in C) and many gaps were formed (arrows in D) in the
monolayer transduced with Ad-FGFR1DN. Scale Bars: 10 mm.
doi:10.1371/journal.pone.0037600.g001
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shortened in cells lacking FGF signaling (Fig. 4B, C), indicating
accelerated degradation of SHP2 in the absence of FGF signaling.
Therefore, we concluded that FGF signaling controls SHP2
expression in endothelial cells at the post translational level. To
understand the pathway of SHP2 degradation, cells transduced
with either Ad-GFP or Ad-FGFR1DN were treated with
proteasome or lysosome inhibitors. Decreased SHP2 expression
in Ad-FGFR1DN cells was rescued by two lysosomal inhibitors
including chloroquine and ammonium chloride, but not with
Figure 2. Suppression of FGF signaling increases Y658 phosphorylation of VE-cadherin and disrupts VE-cadherin/p120-catenin
association. A. Increased VE-cadherin tyrosine phosphorylation in cells lacking FGF signaling. BAEC were transduced with Ad-GFP or Ad-FGFR1DN
and cell lysates were immunoprecipitated (IP) with VE-cadherin antibody. Phosphorylated VE-cadherin was immunoblotted (IB) with
phosphotyrosine-specific (pY20) antibody. The same membrane was reprobed for VE-cadherin. NT denotes non-transduction. B. Tyrosine
phosphorylation of p120-catenin was not affected by FGF inhibition in endothelial cells. BAEC were transduced with Ad-GFP or Ad-FGFR1DN and cell
lysates were immunoprecipitated (IP) with p120-catenin antibody. Phosphorylated p120-catenin was evaluated with phosphotyrosine-specific (pY20)
antibody. The same membrane was reprobed for p120-catenin and VE-cadherin. C. Phosphorylation of VE-cadherin Y658 was increased in cells with
depleted FGF signaling. BAEC were transduced with Ad-GFP or Ad-FGFR1DN. Western blot analysis of total cell lysate using phospho-specific
antibodies shows Y658 phosphorylation was increased in Ad-FGFR1DN transduced cells. D. Quantitative analysis of pY658 VE-cadherin shown in Fig.
2C. The value of NT, standardized with b-tubulin, was designated as 1. (n=3 Mean 6 SD, *P,0.01, by t-test compared with NT control). E. Confluent
BAEC untreated or transduced with either Ad-GFP or Ad-FGFR1DN were starved with 0.5% FBS in EBM-2 for 16 hours and then were stimulated with
50 ng/ml VEGF-A for 15 mins. Total cell lysates were subjected to Western analysis and probed for indicated antibodies. F. Confluent BAEC
monolayers were treated with medium containing FGF-trap (sFGFR1-IIIc or sFGFR3-IIIb), and total cell lysates were subjected to Western blotting.
Medium collected from Ad-GFP transduced cells was used as control. G. Quantitative analysis of pY658 VE-cadherin shown in Fig. 2F. The value of
control, standardized with b-tubulin, was designated as 1. (n=3, Mean 6 SD, *P,0.05, by t-test compared with control). H. Decreased p120-catenin
binding to VE-cadherin in cells lacking FGF signaling. BAEC were transduced with Ad-GFP or Ad-FGFR1DN. Cells were lysed and VE-cadherin was
immunoprecipitated (IP). Immunoprecipitates were subjected to SDS-PAGE followed by immunoblotting (IB) with the indicated antibodies. NT
denotes no transduction. I, J, K. Y658F mutation of VE-cadherin rescued the FGFR1DN phenotype. VE-cadherin-GFP constructs (wild-type or Y658F
mutant) were transfected into HUVEC which were transduced with either Ad-Null or Ad-FGFR1DN. Cells were stained for VE-cadherin (red), VE-
cadherin-GFP (green) and Ad-FGFR1DN (white). Note that wild-type VE-cadherin-GFP was absent from cell-cell contacts in cells lacking FGF signaling
(J) while Y658F VE-cadherin localized at endothelial junctions in the absence of FGF signaling (K). Scale Bars: 10 mm. L. Quantitative analysis of VE-
cadherin distribution. Distribution of transfected VE-cadherin-GFP was evaluated by measuring GFP signal intensity of a 3 mm
2 area set either at cell-
cell junction (J) or cytoplasm (C, adjacent to cell-cell junction, not including Golgi) using Volocity software (Perkin Elmer). In each cell, six-seven
measuring areas were set at J and C region, respectively, and total six cells were evaluated in each treatment group. The data is shown as a ratio of J/
C, mean 6 SEM. *: P,0.01 vs. Wild type VE-cadherin/Ad-Null, **: P,0.01, vs. Wild type VE-cadherin/Ad-FGF-R1DN by t-test.
doi:10.1371/journal.pone.0037600.g002
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lysosome-mediated SHP2 degradation (Fig. 4D, E).
SHP2 Overexpression can Rescue Increased Permeability
following Inhibition of FGF Signaling
Since our observation indicates that SHP2 expression is
impaired in cells transduced with Ad-FGFR1DN, we tested
whether SHP2 overexpression can rescue the phenotypes of
endothelial cells lacking FGF signaling. Adenoviral transduction of
SHP2 into Ad-FGFR1DN-tranduced BAEC resulted in a re-
duction of Y658 VE-cadherin phosphorylation (Fig. 5A, B) and
restoration of VE-cadherin-p120-catenin association as demon-
strated by co-immunoprecipitation (Fig. 5C). In line with these
observations, gap formation in the endothelial monolayer resulting
from FGF signaling inhibition was suppressed by SHP2 over-
expression (Fig. 5D, E, F). Finally, Ad-SHP2 transduction restored
endothelial monolayer resistance that was impaired by Ad-
FGFR1DN (Fig. 5G). These data indicate that SHP2 is capable
of controlling VE-cadherin phosphorylation, thus restoring
impaired endothelial barrier function induced by FGF signaling
inhibition.
Discussion
The results of this study demonstrate that increased permeabil-
ity of the endothelial monolayer after suppression of FGF signaling
is due to the loss of adherens junctions mediated by a decrease in
SHP2 expression that directly leads to increased VE-cadherin
phosphorylation at the Y658 site and the loss of VE-cadherin-p-
120 binding. Several lines of evidence support this conclusion.
Most directly, adenovirus-mediated SHP2 overexpression can
Figure 3. SHP2 is down-regulated and dissociated from VE-cadherin in cells lacking FGF signaling. A. Inhibition of FGF signaling did not
activate Src or FAK. BAEC were transduced with Ad-GFP or Ad-FGFR1DN. Cells in normal growth medium were lysed and total cell lysates were
subjected to SDS-PAGE followed by immunoblotting (IB) with the indicated antibodies. B, C, D, Quantitative analysis of pY416 Src (B), pY527 Src (C),
pY397 Fak (D) shown in Fig. 3A. The value of NT, standardized with b-tubulin, was designated as 1. (n=3). E, F. Reduced SHP2 expression in cells
lacking FGF signaling. Western analysis using BAEC total cell lysates left untreated or transduced with either Ad-GFP or Ad-FGFR1DN. G, Quantitative
analysis of SHP2 levels shown in Fig. 3F. The value of Ad-GFP at MOI 37.5, standardized with b-tubulin, was designated as 1. (n=3 Mean 6 SD,
*P,0.05, by t-test compared with Ad-GFP, MOI 37.5). H, I. VE-cadherin-SHP2 interaction was disrupted by FGF signaling inhibition. BAEC were
transduced with Ad-GFP or Ad-FGFR1DN. Cells were lysed and immunoprecipitated (IP) with anti-VE-cadherin (H) or anti-SHP2 (I) and subjected to
SDS-PAGE followed by immunoblotting (IB) with the indicated antibodies. NT denotes no transduction. J. Catalytically inactive, dominant-negative
SHP2 increased Y658 VE-cadherin phosphorylation. BAEC were transduced with lentivirus wild-typeSHP2 (WT) or dominant-negative-SHP2 (C/S). Cells
were lysed and total cell lystes were subjected to SDS-PAGE followed by immunoblotting (IB) with the indicated antibodies.
doi:10.1371/journal.pone.0037600.g003
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and the loss of VE-cadherin-p120 binding caused by inhibition of
FGF signaling. FGF signaling controls SHP2 protein levels by
inhibiting lysosome-mediated SHP2 degradation with the absence
of FGF signaling input leading to a markedly shortened SHP2
half-life. Finally, the key role of Y658 site phosphorylation is
demonstrated by the rescue of the Ad-FGFR1DN phenotype by
Y658F VE-cadherin mutant. Taken together, these data demon-
strate that FGF signaling potentiates VE-cadherin stability at
endothelial junctions by regulating SHP2 ability to restrain
tyrosine phosphorylation of VE-cadherin.
Many previous studies support the idea that tyrosine
phosphorylation of VE-cadherin and other components of
adherens junctions is associated with impaired barrier function.
Permeability-increasing agents such as histamine, platelet-
activating factor and VEGF all induce tyrosine phosphorylation
of VE-cadherin-catenin complex [9,10,11,12,13]. Although
contributions of Src, FAK and Pyk have been reported, the
balance of inputs regulating VE-cadherin phosphorylation,
however, remains to be fully elucidated [14,16,31]. The
involvement of Src in VE-cadherin phosphorylation is based
on the observations that it associates directly with VE-cadherin,
and that VEGF cannot induce VE-cadherin phosphorylation in
Src-deficient mice or wild-type mice treated with Src inhibitors
[40]. Yet, the precise site of Src-induced phosphorylation in
VE-cadherin is still controversial. In this study, increased VE-
cadherin Y658 phosphorylation was not associated with in-
creased Src activation, suggesting that Src was not the key
player driving the observed phenotype of endothelial cells
lacking FGF signaling. At the same time, there was no increase
in activity of other kinase implicated in VE-cadherin phosphor-
ylation.
These results suggest a possibility that an alternation in PTP
rather than kinase activity is the principal driver of the phenotype.
Figure 4. SHP2 protein stability is impaired in cells lacking FGF signaling. A. SHP2 mRNA levels were not decreased in endothelial cells
lacking FGF signaling. Quantitative RT-PCR analysis of total RNA isolated from BAEC. Total RNA was isolated from BAEC transduced with Ad-GFP or
Ad-FGFR1DN. SHP2 mRNA levels were measured with real-time PCR and normalized to GAPDH expression (Mean 6 SD, *P,0.05, by t-test compared
with NT). NT denotes no transduction. B. Western blotting of total cell lysates isolated from BAEC transduced with Ad-GFP or Ad-FGFR1DN and
treated with 10 mg/ml cycloheximide for up to 36 hours. C. Quantitative analysis of SHP2 Western analysis described in B. The value at time point
0 was designated as 1. (n=3 Mean 6 SD, *P,0.05, by t-test compared with Ad-GFP). D. SHP2 is degraded via the lysosomal pathway in the absence
of FGF signaling. Confluent BAEC transduced with either Ad-GFP or Ad-FGFR1DN were treated with 1 mM MG132, 20 mM lactacystin, 20 mM
chloroquine or 25 mM NH4Cl for 24 hr. Total cell lysates were analyzed by Western blot. E. Quantitative analysis of SHP2 expression shown in Fig. 2D.
The value of Ad-GFP control (DMSO) treatment, standardized with b-tubulin, was designated as 1. (n=3, Mean 6 SD, *P,0.05, by t-test compared
with Ad-FGFR1DN control).
doi:10.1371/journal.pone.0037600.g004
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expression level or localization and not by a specific phosphor-
ylation event. A number of PTPs including DEP-1, VE-PTP
(PTPb), PTPm, PTP1B and SHP2, have been reported to directly
or indirectly associate with VE-cadherin and/or adherens junction
components. PTPm is reported to localize almost exclusively at
endothelial junctions where it associates directly with VE-cadherin
in both human pulmonary artery and lung endothelial cells [20].
In human lung microvascular endothelial cells, PTPm knockdown
impaired endothelial barrier function, whereas overexpression of
PTPm resulted in decreased tyrosine phosphorylation of VE-
cadherin and enhanced barrier function [20]. Similarly, suppres-
sion of VE-PTP or PTP1B causes endothelial barrier dysfunction
[21,39] while DEP-1 co-distributes with VE-cadherin at endothe-
lial cell junctions and controls VE-cadherin-induced inhibition of
VEGFR2 activation [18].
SHP2 has also been shown to associate with VE-cadherin via b-
catenin [22]. Thrombin-induced loss of SHP2 from adherens
junctions correlates with increased tyrosine phosphorylation of
VE-cadherin-catenin complex, leading to adherens junction
disassembly [22]. In the pulmonary endothelium, SHP2 supports
basal endothelial barrier function by coordinating the tyrosine
phosphorylation profile of VE-cadherin-catenin complex and
p190RhoGAP and RhoA activity [41]. In line with these previous
reports, we found that the loss of SHP2 from VE-cadherin in the
setting of FGF signaling inhibition was correlated with increased
tyrosine phosphorylation of VE-cadherin which resulted in
endothelial barrier dysfunction.
Figure 5. Endothelial cell phenotypes derived from FGF inhibition was rescued by SHP2 overexpression. A. Increased phosphorylation
of VE-cadherin Y658 in cells lacking FGF signaling was restored to the basal level by SHP2 overexpression. BAEC were transduced with Ad-FGFR1DN
and Ad-GFP or Ad-SHP2. Cells were lysed and total cell lysates were subjected to SDS-PAGE followed by immunoblotting (IB) with the indicated
antibodies. B. Quantitative analysis of SHP2 shown in Fig. 5A. The value of NT, standardized with b-tubulin, was designated as 1. (n=3 Mean 6 SD,
*P,0.05, by t-test compared with NT, **P,0.05, by t-test compared with Ad-FGFR1DN+Ad-GFP). C. SHP2 overexpression restored p120-catenin/VE-
cadherin association. BAEC were transduced with Ad-FGFR1DN and Ad-GFP or Ad-SHP2. Total cell lysates were isolated and immunoprecipitated with
VE-cadherin antibody. Immunoprecipitates were subjected to SDS-PAGE followed by immunoblotting (IB) with the indicated antibodies using the
same membrane after stripping and reprobing. D, E, Immunostaining of quiescent and fully confluent BAEC transduced with Ad-FGFR1DN (D), or Ad-
SHP2 and Ad-FGFR1DN (E). Cells were stained for VE-cadherin (green), SHP2 (red), and HA (FGFR1DN, blue). Arrows indicate gap formations between
cells. F. Quantitative analysis of immunostaining evaluating the gap formation. Percent of gap area in each image was calculated using NIH Image J
software using 6 different images. Data shown as mean 6 SD *: P,0.05 by t-test. Scale Bars: 10 mm. G. SHP2 overexpression rescued the FGFR1DN
effect on endothelial permeability. BAEC were transduced with Ad-SHP2 and Ad-FGFR1DN, and endothelial monolayer permeability was evaluated
with the ECIS system. Transendothelial resistance was measured every 5 minutes for 17 hours after the onset of adenoviral transduction. NT denotes
no transduction.
doi:10.1371/journal.pone.0037600.g005
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which tyrosine phosphorylation of VE-cadherin is regulated by
SHP2 is of special interest. One study shows that SHP2 is recruited
to VE-cadherin when VEGF receptor tyrosine kinase phosphor-
ylates VE-cadherin. The VE-cadherin-bound SHP2 induces
release of Csk from VE-cadherin potentially by dephosphorylating
its VE-cadherin binding site (Y685). Consequently, c-Src Y527
phosphorylation level decreases, and c-Src Y416 phosphorylation
level increases which in turn results in c-Src activation [42]. In the
current study we observed that SHP2 was associated with VE-
cadherin in resting cells. In cells lacking FGF signaling, SHP2
dissociated from VE-cadherin and the phosphorylation level of
VE-cadherin Y658 increased while phosphorylation levels of Y685
or Y731 were unchanged. Moreover, overexpression of the C/S
mutant of SHP2, a catalytically inactive form of SHP2, in
endothelial cells enhanced Y658 phosphorylation of VE-cadherin,
indicating SHP2 is necessary for dephosphorylating the Y658 site.
Taken together, we propose that SHP2 associates with VE-
cadherin in resting cells, which maintains the Y658 site depho-
sphorylated, leading to the enhancement of endothelial junction
stability, and basal FGF signaling is required for this VE-cadherin-
SHP2 interaction (Fig. 6).
While we show that FGF signaling is required for VE-cadherin-
SHP2 interaction, certain aspects of this regulation remain
uncertain. We found that downregulation of SHP2 expression in
the absence of FGF signaling is due to shortened protein half-life
and that inhibition of the lysosomal pathway, but not the
proteosomal pathway, restored the SHP2 expression levels of cells
lacking FGF signaling. Although we also examined the contribu-
tion of autophagy in this process, we were not able to obtain the
evidence suggesting that FGF signaling controls autophagy in
endothelial cells. Therefore, we concluded that SHP2 is degraded
via lysosomal pathway in the absence of FGF signaling; however,
how FGF controls this process is unclear. Furthermore, the precise
mechanism responsible for FGF-dependent association with SHP2
with VE-cadherin is uncertain. One possibility is that the latter can
occur via the VEGF signaling pathway since VEGF can recruit
SHP2 to VE-cadherin-catenin complex [42,43]. We have recently
demonstrated that VEGF receptor 2 expression is critically
dependent on continuous FGF stimulation [36]. Thus, in the
absence of FGF input VEGF signaling is down-regulated, which in
turn impairs SHP2 recruitment to VE-cadherin.
Finally, it is unclear which FGF is responsible for continuous
stimulation of the endothelium necessary for the maintenance of
SHP2 expression. Endothelial cells express all four FGF tyrosine
kinase receptors and numerous FGF ligands are present in the
serum in vitro and in blood and interstitial fluid in vivo. Given
significant redundancy in the FGF signaling pathways where
multiple ligands can activate multiple receptors, it is virtually
impossible to identify a specific FGF that can be responsible for
this effect. In fact it is likely that multiple redundant ligands are
capable of performing this vital function.
In summary, we report a novel function of FGF signaling in the
vasculature that involves FGF-dependent maintenance of endo-
Figure 6. FGF signaling is required for VE-cadherin-SHP2 interaction which stabilizes adherens junctions. A. Under normal
circumstances, SHP2 is associated with VE-cadherin and dephosphorylates Y658 site of VE-cadherin, which results in p120-catenin coupling,
enhancing VE-cadherin retention at adherens junctions. FGF signaling is required for VE-cadherin-SHP2 interaction. B. In cells expressing the
FGFR1DN construct, SHP2 is downregulated and is not able to associate with VE-cadherin due to the lack of FGF signaling, which increases
phosphorylation level of VE-cadherin Y658, leading to decoupling of p120-catenin; therefore, VE-cadherin stability at cell-cell junctions is impaired.
doi:10.1371/journal.pone.0037600.g006
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